Skip to content

Author

S. Gallinger

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Abstract A105: The PASS-01 Challenge: Comparing Biomarkers for Treatment Selection in Advanced Pancreatic Cancer in a Randomized Controlled Trial

Predictive biomarkers for first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC) have been proposed, but none have been validated using data from a randomized controlled trial (RCT), which is the only design capable of unbiased assessment of differential treatment effect (DTE)....

W. Quan, D. Henault, S. M. Hasnain et al. · 0 citations
Sep 2026

Abstract A140: Patient-derived organoids and precision medicine: Insights from the PASS-01 clinical trial in PDAC

Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage with limited treatment options. Patient-derived organoids (PDOs) can model tumors, identify determinants of therapeutic response, and support precision medicine. In the multi-institutional PASS-01 trial of metastatic PDAC, biopsies f...

A. Habowski, Fatim M. Kouassi, James A. Rouse et al. · 0 citations
Sep 2026

Abstract B066: Convergent cell-state programs characterize BRCA2 -reversion-independent resistance in pancreatic cancer

This work modeled resistance using patient-derived xenografts from two PDACs harboring pathogenic germline BRCA2 variants, and identified convergent transcriptional and epigenetic cell states associated with BRCA2-reversion-independent platinum/PARPi resistance in PDAC.

J. Romero, Yi-Fan Wang, Edward Shanbedi et al. · 0 citations
Sep 2026

Abstract B036: Systematic Germline and Tumor Genomic Analysis for Gene Discovery in Familial Pancreatic Cancer

A systematic discovery pipeline focused on families with multiple affected individuals, leveraging familial segregation and matched tumor analysis to identify novel hereditary PDAC susceptibility genes, highlighting the complexity of hereditary PDAC and support continued genetic and functional evaluation of the priorit...

Jing-Xiong Xu, Y. Goldberg, Amy Zhang et al. · 0 citations
Open access Aug 2026

Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer

MULTIPL demonstrated robust prognostic performance in external validation, identified a subgroup enriched for benefit from GNP, and enabled discovery and validation of prognostic biomarkers in metastatic PDAC, underscoring the value of the PASS-01 Challenge.

W. Quan, D. Henault, A. Zhang et al. · 0 citations
Open access Aug 2026

Multi-modal digital twin model outperforms conventional biomarker stratification in pancreatic cancer

Better patient selection for treatment is critical to improving both cancer care and therapeutic development in oncology. The ability to predict individual patient responses to cancer treatment ahead of time would transform cancer care with substantial impact on outcomes, quality of life and cost. We generated molecula...

M. Griffiths, Jennifer J. Knox, G. O'Kane et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.